<DOC>
	<DOCNO>NCT02843204</DOCNO>
	<brief_summary>The aim study safety efficacy anti-PD-L1 plus NK immunotherapy multiple solid tumor .</brief_summary>
	<brief_title>Combination Anti-PD-L1 NK Immunotherapy Recurrent Solid Tumors</brief_title>
	<detailed_description>By enrol patient solid tumor adapt enrolled criterion , study document first time safety short long term efficacy combine therapy use anti-PD-L1 natural killer ( NK ) cell . The safety evaluate statistic adverse reaction . The efficacy evaluate accord local relief degree , progress free survival ( PFS ) overall survival ( OS ) .</detailed_description>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>All standard therapy fail accord NCCN guideline patient refuse standard therapy cancer recurrence Body tumor 16 , maximum tumor length &lt; 5 cm KPS ≥ 70 , lifespan &gt; 6 month Platelet count ≥ 80×109/L，white blood cell count ≥ 3×109/L , neutrophil count ≥ 2×109/L , hemoglobin ≥ 80 g/L Patients cardiac pacemaker Patients brain metastasis Patients grade 3 hypertension diabetic complication , severe cardiac pulmonary dysfunction</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>solid tumor</keyword>
	<keyword>anti-PD-L1</keyword>
	<keyword>NK immunotherapy</keyword>
</DOC>